Antibe Therapeutics competitors

Yvonne Greenstreet is a COO at ALNYLAM PHARMACEUTICALS, INC..

Sheldon Koenig joined Portola in 2019 and is responsible for leading the Company’s commercial operations. Prior to joining Portola, Mr. Koenig was senior vice president and head of the cardiovascular franchise for Sanofi, where he led the US business operations and global product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the company’s cardiovascular and thrombosis franchises. He has significant overall experience in primary care, specialist, and hospital markets, as well as business development and licensing. Mr. Koenig holds a B.S. from Drexel University and an M.B.A. from Monmouth University.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

John L. Higgins has over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. He is the chief executive officer of [Ligand Pharmaceuticals](https://www.crunchbase.com/organization/ligand-pharmaceuticals#/entity), a biotechnology company that focuses on the discovery and early-stage development of pharmaceuticals for medical needs in the United States. Prior to joining Ligand, Higgins was the chief financial officer; and executive vice president of finance, administration, and corporate development at Connetics Corporation, a public specialty pharmaceutical company, until its acquisition by Stiefel Laboratories, Inc. in 2006. During his service period of nearly 10 years at Connetics, he played a key leadership role in numerous strategic initiatives, including major acquisitions, divestitures, multiple product and technology licensing transactions, and financings. Prior to joining Connetics, Higgins was the executive vice president of corporate development at BioCryst Pharmaceuticals, Inc. and was a member of the health care investment banking team at Dillon, Read & Company, Inc. He has served numerous public and private corporate boards and currently is a director at BioCryst Pharmaceuticals, Inc. where he serves as chairman of the audit committee. Higgins earned a bachelor’s degree in Economics from Colgate University.

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.